Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 53

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 53
---
 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-factand agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys in fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

| Name                |     | Title                                              |     | Date      |
| Marc H. Hedrick, MD |     | President and Chief Executive Officer and Director 
 (Principal Executive Officer)                      |     | [ ], 2025 |
| Andrew Sims         |     | Chief Financial Officer (Principal Financial       
 Officer and Principal Accounting Officer)          |     | [ ], 2025 |
| Richard J. Hawkins  |     | Chairman of the Board                              |     | [ ], 2025 |
| Howard Clowes       |     | Director                                           |     | [ ], 2025 |
| Kyle Guse           |     | Director                                           |     | [ ], 2025 |

II-10

Confidential Treatment Requested by Plus Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83

| Name                    |     | Title    |     | Date      |
| An van Es-Johansson, MD |     | Director |     | [ ], 2025 |
| Robert Lenk, Ph.D.      |     | Director |     | [ ], 2025 |

II-11